Results 211 to 220 of about 8,721 (232)

Studies on the molecular mechanisms underlying pathological consequences of L-serine deficiency caused by genetic Phgdh deletion

, 2013
智子 佐矢野
openalex   +1 more source

Supplementary Fig.S11 from PRMT1 Sustains <i>De Novo</i> Fatty Acid Synthesis by Methylating PHGDH to Drive Chemoresistance in Triple-Negative Breast Cancer

Takehiro Yamamoto, Tetsu Hayashida, Yohei Masugi, Kiyotaka Oshikawa, Noriyo Hayakawa, Mai Itoh, Chiyoko Nishime, Masami Suzuki, Aiko Nagayama, Yuko Kawai, Takako Hishiki, Tomomi Matsuura, Yoshiko Naito, Akiko Kubo, Arisa Yamamoto, Yujiro Yoshioka, Tomokazu Kurahori, Misa Nagasaka, Minako Takizawa, Naoharu Takano, Koji Kawakami, Michiie Sakamoto, Masatoshi Wakui, Takushi Yamamoto, Yuko Kitagawa, Yasuaki Kabe, Kenichi Horisawa, Atsushi Suzuki, Masaki Matsumoto, Makoto Suematsu   +29 more
openalex   +1 more source

Identification of promising lung cancer targets from human plasma proteins via Mendelian randomization. [PDF]

Discov Oncol
Shao XD, Miao ZL, Yu WJ.
europepmc   +1 more source

Supplementary Fig.S8 from PRMT1 Sustains <i>De Novo</i> Fatty Acid Synthesis by Methylating PHGDH to Drive Chemoresistance in Triple-Negative Breast Cancer

Takehiro Yamamoto, Tetsu Hayashida, Yohei Masugi, Kiyotaka Oshikawa, Noriyo Hayakawa, Mai Itoh, Chiyoko Nishime, Masami Suzuki, Aiko Nagayama, Yuko Kawai, Takako Hishiki, Tomomi Matsuura, Yoshiko Naito, Akiko Kubo, Arisa Yamamoto, Yujiro Yoshioka, Tomokazu Kurahori, Misa Nagasaka, Minako Takizawa, Naoharu Takano, Koji Kawakami, Michiie Sakamoto, Masatoshi Wakui, Takushi Yamamoto, Yuko Kitagawa, Yasuaki Kabe, Kenichi Horisawa, Atsushi Suzuki, Masaki Matsumoto, Makoto Suematsu   +29 more
openalex   +1 more source

Some of the next articles are maybe not open access.

Related searches:

Discovery of Novel Drug-like PHGDH Inhibitors to Disrupt Serine Biosynthesis for Cancer Therapy.

Journal of Medicinal Chemistry, 2023
Being the rate-limiting enzyme within the serine biosynthesis pathway, phosphoglycerate dehydrogenase (PHGDH) is abnormally overexpressed in numerous malignant tumor cells and is a promising target for cancer treatment.
Dingding Gao, Shuai Tang, Y. Cen, Liang Yuan, Xiaojing Lan, Qing-Hua Li, Guo-qiang Lin, Min Huang, Ping Tian   +8 more
semanticscholar   +1 more source

PHGDH knockdown increases sensitivity to SR1, an aryl hydrocarbon receptor antagonist, in colorectal cancer by activating the autophagy pathway

The FEBS Journal
Colorectal cancer (CRC) has emerged as the third most prevalent and second deadliest cancer worldwide. Metabolic reprogramming is a key hallmark of cancer cells. Phosphoglycerate dehydrogenase (PHGDH) is over‐expressed in multiple cancers, including CRC.
Hong-ming Li, Xiang Li, Ran Xia, Xing Zhang, Tong-Zhao Jin, Hong-Sheng Zhang   +5 more
semanticscholar   +1 more source

PHGDH Inhibition Overcomes Glioblastoma Resistance to T-cell Therapy.

Cancer Discovery, 2023
Phosphoglycerate dehydrogenase (PHGDH) inhibition improves T-cell therapy efficacy in glioblastoma.

semanticscholar   +1 more source

Abstract 3673: Plk1 phosphorylation of PHGDH to regulate serine metabolism

Cancer Research, 2023
Polo-like kinase 1 (Plk1) has been reported to be highly expressed in most tumors, especially in advanced tumors, while how Plk1 elevation benefits tumor growth remains elusive.

semanticscholar   +1 more source

Structure‐Based Computational Approach in Search of the Potent Molecules Targeting Phosphoglycerate Dehydrogenase (PHGDH) Enzyme for Cancer Treatment

ChemistrySelect
This work aims to target phosphoglycerate dehydrogenase (PHGDH), a promising druggable target, that is overexpressed in various types of cancer. A structure‐based approach was employed to identify novel inhibitors against the enzyme.
Priyanka Solanki, A. Manhas, Dhaval Patel, Prakash C. Jha   +3 more
semanticscholar   +1 more source